Andrea Ulrichsen

Andrea Ulrichsen

Auto-generated profile, based on publicly available information

Andrea Ulrichsen

Department of Psychiatry and Psychotherapy, University Hospital Dresden University of Technology Dresden Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2022 in European Psychiatry
Verified
Journal Article
Open access
PDF file
RSRebecca Strawbridge
Rebecca Strawbridge
Paul McCronePaul McCrone
Paul McCrone
AUAndrea Ulrichsen
Andrea Ulrichsen
RZRoland Zahn
Roland Zahn
JEJonas Eberhard
Jonas Eberhard
AYAllan H. Young
Allan H. Young
Background: Despite well-established guidelines for managing major depressive disorder, its extensive disability burden persists. This Value of Treatment mission from the European Brain Council aimed to elucidate the nature and extent of “gaps” between best-practice and current-practice care, specifically to: 1.Identify current treatment gaps along the care pathway and determine the extent of these gaps in comparison with the stepped-care model and 2.Recommend policies intending to better meet patient needs (i.e., minimize treatment gaps). Methods: After agreement upon a set of relevant treatment gaps, data pertaining to each gap were gathered and synthesized from several sources across six European countries. Subsequently, a modified Delphi approach was undertaken to attain consensus among an expert panel on proposed recommendations for minimizing treatment gaps.Results: Four recommendations were made to increase the depression diagnosis rate (from ~50% episodes), aiming to both increase the number of patients seeking help, and the likelihood of a practitioner to correctly detect depression. These should reduce time to treatment (from ~1 to ~8 years after illness onset) and increase rates of treatment; nine further recommendations aimed to increase rates of treatment (from ~25 to ~50% of patients currently treated), mainly focused on targeting the best treatment to each patient. To improve follow-up after treatment initiation (from ~30 to ~65% followed up within 3 months), seven recommendations focused on increasing continuity of care. For those not responding, 10 recommendations focused on ensuring access to more specialist care (currently at rates of ~5–25% of patients).Conclusions: The treatment gaps in depression care are substantial and concerning, from the proportion of people not entering care pathways to those stagnating in primary care with impairing and persistent illness. A wide range of recommendations can be made to enhance care throughout the pathway.

25 May 2023 in BJPsych Open
Verified
Journal Article
Open access
PDF file
AUAndrea Ulrichsen
Andrea Ulrichsen
EHElliot Hampsey
Elliot Hampsey
RTRosie H. Taylor
Rosie H. Taylor
RGRomayne Gadelrab
Romayne Gadelrab
RSRebecca Strawbridge
Rebecca Strawbridge
Allan YoungAllan Young
Allan Young
Background: Lithium has long been recognised as an effective treatment for bipolar disorder. Its relative efficacy has been measured with a diverse range of clinical outcomes, resulting in differences in efficacy reporting that have not been systematically reviewed. Aims: We aimed to identify and compare the various measures of lithium efficacy employed in interventional studies for people with bipolar disorder. Method: Database (PubMed, Web of Science) and hand searches were performed to identify studies that assessed a clinical response in patients with bipolar disorder who received lithium, up to the end of 2021. We included primary human interventional studies without excluding specific study designs, bipolar disorder subtypes, duration or dosage of lithium treatment. Continuous outcome effects were meta-analysed; binary outcomes were synthesised visually and narratively. The Cochrane risk-of-bias tool was used to assess study-level risk of bias. Results: Seventy-one studies were included (N = 30 542). Approximately two-thirds of participants attained a clinically significant improvement in manic or depressive symptoms, and over 50% achieved remission. About a third required hospital admission (study length 2–12 years) and around 50% needed further treatment to stay well or had recurrence of symptoms; the latter two outcomes tended to be assessed over long-term maintenance periods. Conclusions: An abundance of measurements have been used to assess lithium's clinical effects, across several study designs. Despite the resultant high heterogeneity, an overall picture of lithium's effects emerges that supports previous literature; between half and two-thirds of patients respond well to lithium across varying outcome measures, baseline mood states, study durations and bipolar disorder subtypes.

13 June 2023 in European Psychiatry
Verified
Journal Article
Open access
PDF file
Paul McCronePaul McCrone
Paul McCrone
Allan YoungAllan Young
Allan Young
RZRoland Zahn
Roland Zahn
JEJonas Eberhard
Jonas Eberhard
DWDanuta Wasserman
Danuta Wasserman
RSRebecca Strawbridge
Rebecca Strawbridge
Background: Major depressive disorder (MDD) is highly prevalent across Europe. While evidence-based treatments exist, many people with MDD have their condition undetected and/or untreated. This study aimed to assess the cost-effectiveness of reducing treatment gaps using a modeling approach. Methods: A decision-tree model covering a 27-month time horizon was used. This followed a care pathway where MDD could be detected or not, and where different forms of treatment could be provided. Expected costs pertaining to Germany, Hungary, Italy, Portugal, Sweden, and the UK were calculated and quality-adjusted life years (QALYs) were estimated. The incremental costs per QALY of reducing detection and treatment gaps were estimated. Results: The expected costs with a detection gap of 69% and treatment gap of 50% were €1236 in Germany, €476 in Hungary, €1413 in Italy, €938 in Portugal, €2093 in Sweden, and €1496 in the UK. The incremental costs per QALY of reducing the detection gap to 50% ranged from €2429 in Hungary to €10,686 in Sweden. The figures for reducing the treatment gap to 25% ranged from €3146 in Hungary to €13,843 in Sweden. Conclusions: Reducing detection and treatment gaps, and maintaining current patterns of care, is likely to increase healthcare costs in the short term. However, outcomes are improved, and reducing these gaps to 50 and 25%, respectively, appears to be a cost-effective use of resources.

22 August 2025 in Bipolar Disorders
Verified
Journal Article
Open access
AUAndrea Ulrichsen
Andrea Ulrichsen
EMEsther Mühlbauer
Esther Mühlbauer
LHLisa‐Marie Hartnagel
Lisa‐Marie Hartnagel
ESEmanuel Severus
Emanuel Severus
Anthony CleareAnthony Cleare
Anthony Cleare
UEUlrich Ebner‐Priemer
Ulrich Ebner‐Priemer
Background: Bipolar disorder (BD) is a recurrent disorder, characterised by episodes of (hypo)mania, depression and euthymia with variation in mood, cognition and sleep. Many patients identify changes in sleep before an episode; using daily sleep logs could help identify these changes. Such early warning signs can be a valuable tool for patients and clinicians alike in predicting and preparing for changes in mood. Methods: In the BipoSense study, we followed patients with BD, who were in remission at the start of the study, daily for 1 year. Patients reported for each hour if they were awake or asleep through an app and received fortnightly clinical assessments of bipolar symptoms. We used statistical analyses applying person‐centred data in multilevel logit models to investigate if sleep patterns could differentiate between the period before an episode (prodromal stage) and euthymia, looking at both mean changes and variability of sleep. Bonferroni‐Holm corrections were applied to avoid inflation of type I errors from multiple testing. Results: Twenty‐nine participants were included (mean age 44.0 years [SD = 11.9], female 55% and BD‐I 59%). Waking up later was associated with prodromal depression and was the only significant finding for prodromal mood episodes. Greater variability of sleep duration, total time spent in bed and time waking up were associated with prodromal depression; less variability of time falling asleep and time waking up were linked with prodromal (hypo)mania. Conclusion: Using self‐assessed sleep changes and especially variability can be potential tools in helping patients identify early warning signs of mood recurrence; however, these analyses were explorative and further investigations are warranted.